Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

ADX-914

Subcutaneous administration of ADX-914

DRUG

Placebo

Subcutaneous administration of Placebo

Trial Locations (24)

20774

Visage Clinical Research, Largo

30328

Advanced Medical Research, PC, Sandy Springs

33134

Medical Research Center of Miami, Miami

33173

Well Pharma Medical Research Corporation, Miami

33175

RM Medical Research Inc., Homestead

33612

Apex Clinical Research Center, Painesville

33705

GCP Research, St. Petersburg

35244

Cahaba Dermatology Skin Health Center, Birmingham

47150

Southern Indiana Clinical Trials, New Albany

48084

Revival Research Corporation- Clinedge, Troy

61761

Sneeze wheeze and Itch Associates LLC, Normal

75034

North Texas Center for Clinical Research, Frisco

78213

Progressive Clinical Research, San Antonio

83706

Treasure Valley Medical Research, Boise

84107

JBR Clinical Research, Salt Lake City

90025

California Allergy and Asthma Medical Group- Los Angeles, Los Angeles

90404

Dermatology Institute and Skin Care Center, Santa Monica

90505

Torrance Clinical Research Institute Inc., Torrance

91786

Integrated Research of Inland, Inc., Upland

92708

First OC Dermatology, Fountain Valley

95815

Integrative Skin Science and Research, Sacramento

98004

Dermatology of Seattle & Bellevue, Seattle

99202

Dermatology Specialists of Spokane, Spokane

02919

Clinical Partners, LLC, Johnston

All Listed Sponsors
lead

Q32 Bio Inc.

INDUSTRY